Market Intelligence, Clinical Progress, and High-Purity Reagents for CML & Ph+ ALL Resistance Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ABL T315I drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Mutant Kinase | ABL T315I Recombinant Kinase Domain Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW confirmed. |
View ABL T315I Products |
| Gene Delivery | BCR-ABL T315I Lentivirus / Promise-ORF Full-length gatekeeper mutant ORF for stable Ba/F3 or K562 cell line construction. |
View ABL T315I Products |
| Detection Ab | Anti-ABL1 Recombinant Rabbit mAb Sequence-defined clone for Western Blot, IP, and cellular validation of BCR-ABL expression. |
View ABL T315I Products |
| Validator | ABL1 siRNA Set (3 target-specific + 1 control) For knockdown specificity control in cell-based assays. |
View ABL T315I Products |
| Wild-Type Control | BCR-ABL (Wild Type) Recombinant Kinase Essential for selectivity profiling: mutant vs. ATP-pocket conformation. |
View BCR-ABL Products |
| Pathway Partner | SRC Recombinant Kinase / Lysate Downstream/off-target kinase for cross-reactivity and synthetic lethality panels. |
View SRC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Gatekeeper mutation blocks ATP-competitive binders | ABL T315I mutant protein with verified T315I substitution (mass spec/sequencing confirmed) for direct binding & SPR assays |
| WT vs. Mutant selectivity screening | Matched pair: ABL T315I & BCR-ABL WT proteins (>95% purity) from identical expression systems |
| Off-target kinase liability (SRC, PDGFR, KIT) | Extended kinase panel available; sequence-verified orthologs for selectivity counter-screens |
| Cell-based resistance validation | ABL T315I lentivirus particles for stable isogenic line generation; endotoxin-controlled |
| Lack of assay specificity controls | Validated ABL1 siRNA + recombinant detection antibody included for orthogonal validation |
Live ABL T315I R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ABL T315I therapeutics has entered a precision-focused era, with approved agents like ponatinib and asciminib establishing clinical proof-of-concept. As first-generation resistance is increasingly manageable, the next wave of R&D is targeting compound mutations (e.g., T315I inclusive of E255K or Y253H), allosteric-orthosteric combinations, and targeted protein degradation (PROTACs) to address deep molecular resistance in CML and Ph+ ALL.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ATP-Competitive TKI (3rd/4th Gen) | Takeda (Ponatinib), Ascentage Pharma (Olverembatinib) | CML, Ph+ ALL (T315I-resistant) | Enzymatic inhibition assay (Need active, T315I mutant kinase) |
| Allosteric Inhibitor (STAMP) | Novartis (Asciminib) | CML (chronic phase) | Orthosteric vs. allosteric site competition assay (Need WT + T315I proteins) |
| PROTAC / Degrader | Academic / Biotech partnerships | Relapsed/Refractory Ph+ leukemia | Cellular degradation assay (Need lentivirus-based stable T315I+ cell lines) |
| Combination Therapy | Novartis, Takeda | Multi-resistant CML | Synergy screening in isogenic T315I cell lines |
Molecular Differentiation & Assay Strategy
Differentiation Factors
- Affinity & Kinetics: For ATP-competitive inhibitors, the isoleucine side chain at T315I sterically hinders binding of most second-generation TKIs. Best-in-class molecules require deeper ATP pocket occupancy or conformational adaptability. SPR/BLI measurement of binding kinetics (kon/koff) is a core screening metric.
- Selectivity: Ponatinib's off-target inhibition of SRC, PDGFR, KIT, and FLT3 leads to cardiovascular toxicity. Next-generation molecules must achieve a better therapeutic window between T315I inhibition and kinome selectivity. Use WT vs. mutant proteins for differential scanning fluorimetry (DSF) and kinase panel profiling.
- Mechanism: Allosteric inhibitors bind the myristoyl pocket and are insensitive to gatekeeper mutations, but resistance can arise at the allosteric site (e.g., V299L). Assays must distinguish orthosteric vs. allosteric binding modes.
- Safety & Cellular Function: For PROTACs, the challenge is not overcoming T315I itself but ensuring E3 ligase specificity and avoiding the hook effect. Cellular assays should measure endogenous BCR-ABL T315I degradation and downstream signaling (e.g., p-STAT5).
Screening Assay Recommendations
- Biochemical Kinase Inhibition Assay: Use high-purity (>95%), sequence-verified ABL T315I recombinant kinase domain under optimized ATP-Km conditions.
- Differential Scanning Fluorimetry (DSF): Rapid high-throughput screening for small-molecule binding to T315I mutant protein, compared to WT for selectivity window.
- Surface Plasmon Resonance (SPR): Immobilize ABL T315I protein to measure kinetic parameters (KD, kon, koff) of small molecules or ligands.
- Cell Proliferation & Apoptosis Assays: Use TarMart BCR-ABL T315I lentivirus to construct stable Ba/F3 or K562 cell lines for 72-hour proliferation inhibition (e.g., CellTiter-Glo) and apoptosis detection.
- Degradation Assay (for PROTACs): In T315I stable cell lines, use anti-ABL1 antibody to detect BCR-ABL protein level changes after compound treatment, with ABL1 siRNA control to exclude off-target degradation.
Related Target Recommendations
- BCR-ABL (Wild Type): Essential as a wild-type control for selectivity window assessment.
- SRC: Key downstream signaling molecule and major off-target kinase for many TKIs; recombinant SRC protein is critical for safety screening and synthetic lethality studies.
- ABL2 (ARG): Highly homologous to ABL1; compensatory activation can occur in resistance contexts. ABL2 protein enables broader subfamily off-target screening.